JSP191 (Briquilimab)
A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 as a Second-line Therapy in Subjects With Lower-Risk Myelodysplastic Syndrome (LR-MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 30 patients (estimated)
- Sponsors
- Jasper Therapeutics, Inc.
- Tags
- Monoclonal Antibody
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1751
- NCT Identifier
- NCT05903274
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.